(MTD) Mettler-Toledo International - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 22.107m USD | Total Return: -5.3% in 12m

Precision Balances, Analytical Instruments, Industrial Scales, Inspection
Total Rating 50
Safety 74
Buy Signal -0.43
Diagnostics & Research
Industry Rotation: +1.9
Market Cap: 22.1B
Avg Turnover: 211M
Risk 3d forecast
Volatility29.4%
VaR 5th Pctl5.02%
VaR vs Median3.71%
Reward TTM
Sharpe Ratio-0.01
Rel. Str. IBD11
Rel. Str. Peer Group22.4
Character TTM
Beta1.046
Beta Downside1.277
Hurst Exponent0.465
Drawdowns 3y
Max DD36.61%
CAGR/Max DD-0.16
CAGR/Mean DD-0.42
EPS (Earnings per Share) EPS (Earnings per Share) of MTD over the last years for every Quarter: "2021-03": 6.56, "2021-06": 8.1, "2021-09": 8.72, "2021-12": 10.53, "2022-03": 7.87, "2022-06": 9.39, "2022-09": 10.18, "2022-12": 12.1, "2023-03": 8.69, "2023-06": 10.19, "2023-09": 9.8, "2023-12": 9.4, "2024-03": 8.89, "2024-06": 9.65, "2024-09": 10.21, "2024-12": 12.41, "2025-03": 8.19, "2025-06": 10.09, "2025-09": 11.15, "2025-12": 13.36, "2026-03": 8.91,
EPS CAGR: 3.30%
EPS Trend: 61.0%
Last SUE: 0.59
Qual. Beats: 0
Revenue Revenue of MTD over the last years for every Quarter: 2021-03: 804.39, 2021-06: 924.351, 2021-09: 951.95, 2021-12: 1037.239, 2022-03: 897.791, 2022-06: 978.387, 2022-09: 985.846, 2022-12: 1057.685, 2023-03: 928.738, 2023-06: 982.117, 2023-09: 942.462, 2023-12: 934.992, 2024-03: 925.949, 2024-06: 946.75, 2024-09: 954.535, 2024-12: 1045.127, 2025-03: 883.744, 2025-06: 983.221, 2025-09: 1029.699, 2025-12: 1129.735, 2026-03: 947.127,
Rev. CAGR: 1.56%
Rev. Trend: 50.9%
Last SUE: 0.39
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: MTD Mettler-Toledo International

Mettler-Toledo International Inc. (MTD) is a global manufacturer of precision instruments and services, operating through specialized segments in the Americas, Europe, and Asia. The company’s portfolio spans laboratory analytics, industrial weighing systems, and retail packaging solutions, serving diverse end-markets including pharmaceuticals, food production, and logistics.

As a leader in the Life Sciences Tools & Services sub-industry, Mettler-Toledo utilizes a high-margin business model focused on mission-critical equipment where precision is non-negotiable for regulatory compliance. The sector is characterized by high switching costs and significant recurring revenue through software integration and maintenance services.

Investors can evaluate the company’s valuation metrics and historical growth trends by exploring the detailed data available on ValueRay.

The company maintains a strong competitive moat through its proprietary LabX software platform, which automates workflows and centralizes data management for research and testing facilities. MTD reaches its global customer base through a dual strategy of direct sales forces and indirect distribution channels.

Headlines to Watch Out For
  • Biopharma R&D spending levels dictate demand for high-margin laboratory instrumentation
  • Industrial automation trends drive growth in inspection and weighing solution segments
  • Economic recovery in China impacts revenue across laboratory and industrial business units
  • Direct sales model maintains premium pricing power and high operating margins
  • Sustained share buyback programs significantly influence earnings per share and valuation
Piotroski VR-10 (Strict) 6.5
Net Income: 875.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.22 > 0.02 and ΔFCF/TA -5.23 > 1.0
NWC/Revenue: 5.47% < 20% (prev 0.39%; Δ 5.07% < -1%)
CFO/TA 0.25 > 3% & CFO 901.1m > Net Income 875.1m
Net Debt (2.26b) to EBITDA (1.27b): 1.77 < 3
Current Ratio: 1.20 > 1.5 & < 3
Outstanding Shares: last quarter (20.3m) vs 12m ago -2.79% < -2%
Gross Margin: 57.79% > 18% (prev 0.58%; Δ 5.72k% > 0.5%)
Asset Turnover: 118.5% > 50% (prev 118.4%; Δ 0.07% > 0%)
Interest Coverage Ratio: 16.63 > 6 (EBITDA TTM 1.27b / Interest Expense TTM 68.9m)
Altman Z'' 10.00
A: 0.06 (Total Current Assets 1.33b - Total Current Liabilities 1.11b) / Total Assets 3.67b
B: 2.56 (Retained Earnings 9.41b / Total Assets 3.67b)
C: 0.33 (EBIT TTM 1.15b / Avg Total Assets 3.45b)
D: 2.44 (Book Value of Equity 9.06b / Total Liabilities 3.71b)
Altman-Z'' = 13.55 = AAA
Beneish M -2.93
DSRI: 1.04 (Receivables 708.2m/638.4m, Revenue 4.09b/3.83b)
GMI: 1.01 (GM 57.79% / 58.26%)
AQI: 1.03 (AQ_t 0.41 / AQ_t-1 0.40)
SGI: 1.07 (Revenue 4.09b / 3.83b)
TATA: -0.01 (NI 875.1m - CFO 901.1m) / TA 3.67b)
Beneish M = -2.93 (Cap -4..+1) = A
What is the price of MTD shares?

As of May 27, 2026, the stock is trading at USD 1101.33 with a total of 108,645 shares traded.
Over the past week, the price has changed by +2.46%, over one month by -13.60%, over three months by -20.03% and over the past year by -5.29%.

Is MTD a buy, sell or hold?

Mettler-Toledo International has received a consensus analysts rating of 3.62. Therefore, it is recommended to hold MTD.

  • StrongBuy: 4
  • Buy: 0
  • Hold: 9
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the MTD price?
Analysts Target Price 1327.8 20.6%
Mettler-Toledo International (MTD) - Fundamental Data Overview as of 23 May 2026
Market Cap USD = 22.1b (22.1b USD * 1.0 USD.USD)
P/E Trailing = 25.723
P/E Forward = 23.31
P/S = 5.4055
P/B = 1328.2277
P/EG = 2.2868
Revenue TTM = 4.09b USD
EBIT TTM = 1.15b USD
EBITDA TTM = 1.27b USD
Long Term Debt = 2.16b USD (from longTermDebt, last quarter)
Short Term Debt = 67.0m USD (from shortTermDebt, last quarter)
Debt = 2.32b USD (from shortLongTermDebtTotal, last quarter) + Leases 88.9m
Net Debt = 2.26b USD (calculated: Debt 2.32b - CCE 60.6m)
Enterprise Value = 24.4b USD (22.1b + Debt 2.32b - CCE 60.6m)
Interest Coverage Ratio = 16.63 (Ebit TTM 1.15b / Interest Expense TTM 68.9m)
EV/FCF = 30.69x (Enterprise Value 24.4b / FCF TTM 793.8m)
FCF Yield = 3.26% (FCF TTM 793.8m / Enterprise Value 24.4b)
FCF Margin = 19.41% (FCF TTM 793.8m / Revenue TTM 4.09b)
Net Margin = 21.40% (Net Income TTM 875.1m / Revenue TTM 4.09b)
Gross Margin = 57.79% ((Revenue TTM 4.09b - Cost of Revenue TTM 1.73b) / Revenue TTM)
Gross Margin QoQ = 58.68% (prev 58.05%)
Tobins Q-Ratio = 6.64 (Enterprise Value 24.4b / Total Assets 3.67b)
Interest Expense / Debt = 2.97% (Interest Expense 68.9m / Debt 2.32b)
Taxrate = 19.17% (40.2m / 209.7m)
NOPAT = 925.6m (EBIT 1.15b * (1 - 19.17%))
Current Ratio = 1.20 (Total Current Assets 1.33b / Total Current Liabilities 1.11b)
 Debt / Equity = -55.33 (negative equity) (Debt 2.32b / totalStockholderEquity, last quarter -41.9m)
 Debt / EBITDA = 1.77 (Net Debt 2.26b / EBITDA 1.27b)
Debt / FCF = 2.84 (Net Debt 2.26b / FCF TTM 793.8m)
Total Stockholder Equity = -143.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 25.35% (Net Income 875.1m / Total Assets 3.67b)
 RoE = -610.3% (negative equity) (Net Income TTM 875.1m / Total Stockholder Equity -143.4m)
 RoCE = 56.74% (EBIT 1.15b / Capital Employed (Equity -143.4m + L.T.Debt 2.16b))
RoIC = 36.06% (NOPAT 925.6m / Invested Capital 2.57b)
WACC = 8.97% (E(22.1b)/V(24.4b) * Re(9.66%) + D(2.32b)/V(24.4b) * Rd(2.97%) * (1-Tc(0.19)))
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -100.00 | Cagr: -2.93%
[DCF] Terminal Value 71.94% ; FCFF base≈823.9m ; Y1≈767.2m ; Y5≈698.9m
[DCF] Fair Price = 383.9 (EV 10.0b - Net Debt 2.26b = Equity 7.76b / Shares 20.2m; r=8.97% [WACC]; 5y FCF grow -8.65% → 2.50% )
EPS Correlation: 60.97 | EPS CAGR: 3.30% | SUE: 0.59 | # QB: 0
Revenue Correlation: 50.89 | Revenue CAGR: 1.56% | SUE: 0.39 | # QB: 0
EPS current Quarter (2026-06-30): EPS=10.79 | Chg30d=-1.40% | Revisions=-38% | Analysts=10
EPS next Quarter (2026-09-30): EPS=12.08 | Chg30d=-0.57% | Revisions=-8% | Analysts=10
EPS current Year (2026-12-31): EPS=46.64 | Chg30d=+0.29% | Revisions=+53% | GrowthEPS=+9.2% | GrowthRev=+5.3%
EPS next Year (2027-12-31): EPS=51.28 | Chg30d=+0.16% | Revisions=-6% | GrowthEPS=+9.9% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +53%